Skip to content

Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid

Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02891642
Enrollment
1000
Registered
2016-09-07
Start date
2016-09-30
Completion date
2021-02-28
Last updated
2020-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ascites, Malignancy, Pleural Diseases, Pleural Effusion

Keywords

malignancy, Pleural Effusion, Pleural Neoplasms, Ascites

Brief summary

The purpose of the current study is to establish a Liquid biopsy method (positive enrichment by a novel immunomagnetic beads capture assay) for detection of malignant cell in serous effusions and to evaluate its sensitivity and specificity for clinical application.

Detailed description

A serous effusion is common event in metastatic carcinoma, but it also can be associated with other benign medical conditions. Current standard method for detecting malignancy is by cytological examination. However, cytological examination is often low sensitive, often due to the large amount of fluid with relatively sparse tumor cells present and the presence of many normal cells such as mesothelial cell. The investigators have developed a new method, malignant cell enrichment with immunomagnetic beads capture followed by Pap staining and NGS, to identify target malignant cells in body fluids. McAb NJ001 is developed for malignant cell isolation with immunomagnetic beads capture technique. This is a prospective, multi-center, double-blind, statistically powered clinical trial that will enroll patients scheduled to undergo a procedure for removal of fluid from a serous effusion with or without clinical diagnosis of caner. The purpose of the current study is to compare the novel serous effusion detection assay using NJ001 coated immunomagnetic beads capture followed by Pap staining and NGS analysis with traditional cytologic evaluation.

Interventions

Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.

Sponsors

University of California, Los Angeles
CollaboratorOTHER
M.D. Anderson Cancer Center
CollaboratorOTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CollaboratorOTHER
Jiangsu Cancer Institute & Hospital
CollaboratorOTHER
Anhui Provincial Hospital
CollaboratorOTHER_GOV
Sir Run Run Shaw Hospital
CollaboratorOTHER
Renmin Hospital of Wuhan University
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Males or females \>18 years of age; * Have a serous effusion; * Scheduled for a diagnostic and/or therapeutic procedure to remove serous fluid ( Puncture of serous cavity).

Exclusion criteria

* Females known to be pregnant;

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants with Malignancies Assessed by the Liquid Biopsy with Immunomagnetic Beads Capture Technique (Cancer Cell Positive Enrichment)The samples will be analyzed within 18 monthsSP70 positive

Countries

China

Contacts

Primary ContactJian Xu, MD/ PhD
xu_jian79@163.com+8602568135230

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026